Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%
Lithium
44.60
(0.19%)
Gold
2,668.10
0.23%
Copper
4.21
1.72%
Oil
70.17
2.95%
Bitcoin
95,147.74
(0.74%)
FTSE 100
8,359.41
0.56%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,722.51
(0.11%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
0.11%
Hang Seng
19,746.32
0.82%

PYC Therapeutics Ltd

PYC

ASX

PYC Therapeutics (PYC) is a clinical-stage biotechnology company at the forefront of developing a new generation of RNA therapies. Their mission is to create life-changing treatments for patients suffering from genetic diseases. PYC leverages its innovative drug delivery platform to significantly improve the effectiveness of these precision medicines. This platform tackles a major hurdle within the rapidly growing and commercially validated field of RNA therapeutics. PYC pioneered the journey of bringing a drug candidate for a childhood blinding eye disease into human trials, and they are now actively advancing multiple promising "fast-follower" programs towards clinical evaluation.

Latest Posts

Line Chart with Gradient
Price
$1.690
0.01 (0.6%)
At Close 02/12 (AEST)
Related Companies
RADIOPHARM THERANOSTICS LIMITED
$RAD
PRESCIENT THERAPEUTICS LIMITED
$PTX
DORSAVI LTD
$DVL
WELLFULLY LIMITED
$WFL
AROA BIOSURGERY LIMITED
$ARX

Leave a Comment on PYC


Comments for PYC

    Latest Posts

    pyc-therapeutics-asx-pyc-advances-towards-human-trials-for-pkd-treatment-pyc
    Health Care $PYC
    PYC Therapeutics (ASX: $PYC) advances towards human trials for PKD treatmentPYC-003 drug candidate shows promise for Autosomal Dominant Polycystic Kidney Disease in pre-clinical studies
    November 27, 2024
    pyc-therapeutics-asx-pyc-shares-promising-rp11-trial-data-pyc
    Health Care $PYC
    PYC Therapeutics (ASX: $PYC) shares promising RP11 trial dataVP-001 shows improved vision in patients, preparing for FDA registrational trial in 2025
    November 22, 2024
    pyc-therapeutics-asx-pyc-advances-final-patient-cohort-dosing-pyc
    Health Care $PYC
    PYC Therapeutics (ASX: $PYC) advances final patient cohort dosingSafety Review Committee approves escalation in VP-001 Multiple Ascending Dose study for RP11 treatment
    November 5, 2024
    pyc-therapeutics-asx-pyc-initiates-clinical-trial-for-rare-eye-disease-pyc
    Health Care $PYC
    PYC Therapeutics (ASX: $PYC) initiates clinical trial for rare eye diseaseThe company begins trial for PYC-001 to treat Autosomal Dominant Optic Atrophy, marking a major milestone
    November 1, 2024
    pyc-therapeutics-asx-pyc-receives-orphan-drug-designation-for-vp-001-pyc
    Health Care $PYC
    PYC Therapeutics (ASX: $PYC) receives orphan drug designation for VP-001FDA grants Orphan Drug Designation for VP-001 targeting rare eye disease, Retinitis Pigmentosa type 11
    October 21, 2024
    pyc-therapeutics-asx-pyc-to-start-human-trials-in-second-blinding-eye-disease-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) to start human trials in second blinding eye disease

    Receives HREC approval to commence clinical trials of drug candidate PYC-001 for Autosomal Dominant Optic Atrophy

    August 15, 2024
    pyc-therapeutics-asx-pyc-progresses-rp11-clinical-trial-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) progresses RP11 clinical trial

    Developing investigational drug for Retinitis Pigmentosa type 11 patients

    August 5, 2024
    pyc-therapeutics-asx-pyc-progresses-pipeline-programs-in-q2-2024-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) progresses pipeline programs in q2 2024

    Company achieves key milestones in drug development and secures funding for future trials

    July 22, 2024
    pyc-therapeutics-asx-pyc-commences-rp11-multiple-dose-trial-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) commences rp11 multiple dose trial

    Initiates study to evaluate safety and efficacy of investigational drug candidate for RP11 patients

    July 10, 2024
    pyc-therapeutics-asx-pyc-restores-missing-protein-in-phelan-mcdermid-syndrome-neurons-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) restores missing protein in Phelan-McDermid Syndrome neurons

    Develops RNA drug candidate for PMS, progresses towards human trials in 2025

    June 7, 2024
    pyc-therapeutics-asx-pyc-progresses-blinding-eye-disease-drug-into-human-trials-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) progresses blinding eye disease drug into human trials

    Drug candidate PYC-001 demonstrates potential for Autosomal Dominant Optic Atrophy treatment

    May 14, 2024
    pyc-therapeutics-asx-pyc-presents-rp11-clinical-trial-data-at-arvo-conference-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) presents RP11 clinical trial data at ARVO conference

    Associate Professor Fred Chen to present safety and efficacy data of VP-001 at ARVO conference

    May 6, 2024
    pyc-therapeutics-asx-pyc-progresses-rp11-drug-candidate-to-mid-stage-human-trials-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) progresses rp11 drug candidate to mid-stage human trials

    Safety and tolerability of VP-001 confirmed, advancing to Multiple Ascending Dose study

    April 29, 2024
    pyc-therapeutics-asx-pyc-progresses-drug-candidates-in-q1-2024-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) progresses drug candidates in Q1 2024

    Company advances precision medicines for blinding eye diseases and kidney disease

    April 26, 2024
    pyc-therapeutics-asx-pyc-conducts-pro-rata-entitlement-offer-to-raise-74-6-million-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) conducts pro-rata entitlement offer to raise $74.6 million

    Equity raising to fund drug development and research activities

    March 20, 2024
    pyc-therapeutics-asx-pyc-completes-dosing-in-rp11-patient-cohort-3-pyc
    Health Care $PYC

    PYC Therapeutics (ASX: $PYC) completes dosing in RP11 patient cohort 3

    Preparing for open-label Multiple Ascending Dose study in RP11 patients

    February 28, 2024

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) advances towards human trials for PKD treatment

    PYC-003 drug candidate shows promise for Autosomal Dominant Polycystic Kidney Disease in pre-clinical studies

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) shares promising RP11 trial data

    VP-001 shows improved vision in patients, preparing for FDA registrational trial in 2025

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) advances final patient cohort dosing

    Safety Review Committee approves escalation in VP-001 Multiple Ascending Dose study for RP11 treatment

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) initiates clinical trial for rare eye disease

    The company begins trial for PYC-001 to treat Autosomal Dominant Optic Atrophy, marking a major milestone

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) receives orphan drug designation for VP-001

    FDA grants Orphan Drug Designation for VP-001 targeting rare eye disease, Retinitis Pigmentosa type 11

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) to start human trials in second blinding eye disease

    Receives HREC approval to commence clinical trials of drug candidate PYC-001 for Autosomal Dominant Optic Atrophy

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) progresses RP11 clinical trial

    Developing investigational drug for Retinitis Pigmentosa type 11 patients

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) progresses pipeline programs in q2 2024

    Company achieves key milestones in drug development and secures funding for future trials

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) commences rp11 multiple dose trial

    Initiates study to evaluate safety and efficacy of investigational drug candidate for RP11 patients

    PYC

    $PYC

    PYC Therapeutics (ASX: $PYC) restores missing protein in Phelan-McDermid Syndrome neurons

    Develops RNA drug candidate for PMS, progresses towards human trials in 2025

    Load More
    No More Posts
    Related Companies
    ANATARA LIFESCIENCES LTD
    $ANR
    TELIX PHARMACEUTICALS LIMITED
    $TLX
    IMMUTEP LIMITED
    $IMM
    ANTEOTECH LTD
    $ADO
    ORTHOCELL LIMITED
    $OCC

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions